Johnson & Johnson Receives Subpoenas

Johnson & Johnson today announced that it has received separate subpoenas from the U.S. Attorney's Office in Philadelphia, the U.S. Attorney's Office in Boston and the U.S. Attorney's Office in San Francisco. The subpoenas relate to investigations by those three offices previously disclosed in SEC filings and directed, respectively, to sales and marketing of RISPERDAL® by Janssen, L.P., TOPAMAX® by Ortho-McNeil and NATRECOR® by Scios Inc. – each subsidiaries of Johnson & Johnson.

The subpoenas request information regarding Johnson & Johnson's corporate supervision and oversight of these three subsidiaries, including their sales and marketing of these drugs.

Johnson & Johnson will cooperate in responding to these requests.